Tislelizumab
As of the edition of 20 October 2026, Tislelizumab is an antibody: marketed, first approved in 2023 (EU); acts on PDCD1; US protection ends in 2036.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Antibody
- Brand name
- Tevimbra
- First approved
- 15 September 2023 (EU)
- Approvals on record
- 4 in 3 regions
- Holder of the most recent approval
- BeiGene; 3 holders in all
- Registered trials
- 558, 35 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Urinary and reproductive; Skin and connective tissue; Pregnancy and women's health
US protection
US protection ends in 2036.
US protection ends in 2036, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by BeiGene. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
Companies that need a new molecule because of this drug
2 companies on route B and 2 companies on route A because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Tislelizumab.
Companies on route A for this drug
In the product2 companies are on route A because of Tislelizumab.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PDCD1 | Programmed cell death protein 1 | Q15116 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 31 | 3 | 16 | 0 |
| Phase 1 | 67 | 13 | 35 | 10 |
| Phase 2 | 393 | 62 | 205 | 17 |
| Phase 3 | 60 | 11 | 38 | 8 |
| Phase 4 | 7 | 0 | 5 | 0 |
| All trials | 558 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| BeiGene | Applicant, Acquired holder and Lead sponsor of trials | 2015 to now |